Trial Profile
A phase II study of ADX-1612 for the treatment of lymphoproliferative immune disease
Status:
Suspended
Phase of Trial:
Phase II
Latest Information Update: 16 Mar 2020
Price :
$35
*
At a glance
- Drugs Ganetespib (Primary)
- Indications Lymphoproliferative disorders
- Focus Therapeutic Use
- 12 Mar 2020 According to an Aldeyra Therapeutics media release, the company has elected to place on hold clinical development of ADX-1612 for the treatment of post-transplant lymphoproliferative disorder. This initiative prioritizes Aldeyra ocular portfolio.
- 12 Mar 2020 Status changed from planning to suspended, according to an Aldeyra Therapeutics media release.
- 09 May 2019 According to an Aldeyra Therapeutics media release, this study is expected to initiate in the second half of 2019.